Transaction · 0001231919-26-001106

Mpm Bioventures 2018, L.P.

MPM BIOVENTURES 2018, L.P., 10%, reported an open-market or private sale at Entrada Therapeutics, Inc. involving 14569.000000 shares for an estimated $102857.14. Reported holdings after the transaction were 4318348.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code S10%
TRDAEntrada Therapeutics, Inc.
Trade date
Aug 26, 2026
Filing date
Aug 27, 2026
View on SEC Insider profile
Estimated value-$102kShares × reported price
Shares traded14.5k$7.06 per share
Holdings after4.31MIndirect · See Footnote
% of reported position traded0.34%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 4,332,917 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

TRDA price since this filing

Daily closing prices, with the filing date and available return windows
TRDA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d -1.4%30d -15.3%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001231919-26-001106
Common Stock
Transaction date
Aug 26, 2026
Filed Aug 27, 2026, 01:27 AM · 1d delay
Shares
14,569 sh
$7.06 per share
Estimated value
-$102k
Computed from shares × price
Holdings after
4,318,348 sh
Indirect · See Footnote

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Repeat Seller
Filing-only score

+4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector No10% YesOther No
Footnotes & amended
  1. F1

    The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1…

  2. 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC")…

  3. partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2…

  4. manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

  5. F2

    Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of th…

  6. (2 footnotes)

    the number of shares sold at each separate price within the range set forth in this Form 4.

  7. F3

    The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018.

  8. F4

    Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

  9. F5

    The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018.

  10. F6

    Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of th…

  11. F7

    The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018.

  12. F8

    The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018.

  13. F9

    Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the…

  14. F10

    The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018.

Original filing · 0001231919-26-001106
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

TRDA